Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Women's Health
Published in: BMC Women's Health 1/2023

Open Access 01-12-2023 | ICSI | Research

Nomogram to predict FSH starting dose in poor ovarian response women in progestin primed ovarian stimulation protocol

Authors: Shuxie Wu, Yanping Li, Gao Wu, Hanbin Wu

Published in: BMC Women's Health | Issue 1/2023

Login to get access

Abstract

Prediction of individual ovarian response to exogenous gonadotropin is a cornerstone for success and safety in all controlled ovarian stimulation (COS) protocols. Providing the best FSH starting dose according to each woman’s own characteristics is the key to the success of individualized treatment. The objective of this investigation was to evaluate the potential application of a novel nomogram based on antral follicle counting (AFC), anti-Müllerian hormone (AMH) and body mass index (BMI) as a tool to optimize the follicle-stimulating hormone (FSH) starting dose in women with poor ovarian response in in-vitro fertilization (IVF)/intra-cytoplasmic sperm injection (ICSI) cycles in progestin-primed ovarian stimulation (PPOS). We performed a retrospective analysis involving 130 poor ovarian responders undergoing IVF/ICSI cycles in a PPOS protocol from June 2017 to February 2019 in our reproductive center. The individual FSH starting dose was selected according to patients’ clinical history and characteristics. The influence of variables including age, BMI, AMH and AFC on the FSH starting dose was assessed through multiple regression analysis. We used the variables reaching the statistical significance for calculation for the final predictive model. In the univariate analysis, BMI, AMH and AFC were significant (P < 0.05) predictors of FSH starting dose, age was canceled. In the multivariate analysis, BMI, AMH and AFC remained significant (P < 0.05). According to the nomogram, 118 patients (90.77% of 130) would have received a higher FSH starting dose and 12 patients (9.23% of 130) a lower FSH starting dose than practice dose. The application of the nomogram based on three variables easily determined in clinical practice: BMI, AMH and AFC would lead to a more tailored FSH starting dose in women with poor ovarian response.
Literature
1.
Zhu X, Ye J, Fu Y, et al. The effect of human chorionic gonadotrophin contained in human menopausal gonadotropin on the clinical outcomes during progestin-primed ovarian stimulation. Oncotarget. 2017;8(50):87340–52.CrossRefPubMedPubMedCentral
2.
Chen Q, Wang Y, Sun L, et al. Controlled ovulation of the dominant follicle using progestin in minimal stimulation in poor responders. Reprod Biol Endocrinol. 2017;15(1):71.CrossRefPubMedPubMedCentral
3.
Wang N, Wang Y, Chen Q, et al. Luteal-phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study. Clin Endocrinol (Oxf). 2016;84(5):720–8.CrossRefPubMed
4.
Dong J, Wang Y, Chai WR, et al. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG. 2017;124(7):1048–55.CrossRefPubMed
5.
Wang Y, Chen Q, Wang N, et al. Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: a double-blind randomized crossover clinical trial. Med (Baltim). 2016;95(9):e2939.CrossRef
6.
Kuang Y, Chen Q, Hong Q, et al. Luteal-phase ovarian stimulation case report: three-year follow-up of a Twin Birth. J IVF Reprod Med Genet. 2013;1(2):106–8.CrossRef
7.
Wen X, Kuang Y, Zhou L et al. Lipidomic Components Alterations of Human Follicular Fluid Reveal the Relevance of Improving Clinical Outcomes in Women Using Progestin-Primed Ovarian Stimulation Compared to Short-Term Protocol. 2018, 24:3357–3365.
8.
Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017;23(2):211–20.PubMed
9.
Chen YM, Qi QR, Xie QZ, et al. Effect of progestin primed ovarian stimulation protocol on outcomes of aged infertile women who failed to get pregnant in the first IVF/ICSI cycle:a self controlled study. Curr Med Sci. 2018;38(3):513–8.CrossRefPubMed
10.
Kuang Y, Chen Q, Hong Q, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod Biomed Online. 2014;29(6):684–91.CrossRefPubMed
11.
Huang P, Tang M, Qin A. Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ICSI compared to a GnRH antagonist protocol: a retrospective study. J Gynecol Obstet Hum Reprod. 2019;48(2):99–102.CrossRefPubMed
12.
Moon KY, Kim H, Lee JY, et al. Nomogram to predict the number of oocytes retrieved in controlled ovarian stimulation. Clin Exp Reprod Med. 2016;43(2):112–8.CrossRefPubMedPubMedCentral
13.
Sighinolfi G, Grisendi V, La Marca A. How to personalize ovarian stimulation in clinical practice. J Turk Ger Gynecol Assoc. 2017;18(3):148–53.PubMedPubMedCentral
14.
Pouly JL, Olivennes F, Massin N, et al. Usability and utility of the CONSORT calculator for FSH starting doses: a prospective observational study. Reprod Biomed Online. 2015;31(3):347–55.CrossRefPubMed
15.
La Marca A, Grisendi V, Giulini S, et al. Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count. J Ovarian Res. 2013;6(1):11.CrossRefPubMedPubMedCentral
16.
Ashrafi M, Arabipoor A, Yahyaei A et al. Does the “delayed start” protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? A randomized clinical trial.Reprod Biol Endocrinol.2018,16(1):124.
17.
18.
Patrizio P, Vaiarelli A, Levi Setti PE, et al. How to define, diagnose and treat poor responders? Responses from a worldwide survey of IVF clinics. Reprod Biomed Online. 2015;30(6):581–92.CrossRefPubMed
19.
Papaleo E, Zaffagnini S, Munaretto M, et al. Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study. Eur J Obstet Gynecol Reprod Biol. 2016;207:94–9.CrossRefPubMed
20.
Allegra A, Marino A, Volpes A, et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reprod Biomed Online. 2017;34(4):429–38.CrossRefPubMed
21.
Di Paola R, Garzon S, Giuliani S, et al. Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman’s age and markers of ovarian reserve. Arch Gynecol Obstet. 2018;298(5):1029–35.CrossRefPubMed
22.
Zhao X, Ma B, Mo S, et al. Improvement of pregnancy outcome by extending embryo culture in IVF-ET during clinical application. J Assist Reprod Genet. 2018;35(2):321–9.CrossRefPubMed
23.
Sighinolfi G, Sunkara SK, La Marca A. New strategies of ovarian stimulation based on the concept of ovarian follicular waves: from conventional to random and double stimulation. Reprod Biomed Online. 2018;37(4):489–97.CrossRefPubMed
24.
Liu Y, Chen Q, Yu S, et al. Progestin-primed ovarian stimulation with or without clomiphene citrate supplementation in normal ovulatory women undergoing in vitro fertilization/intracytoplasmic sperm injection: a prospective randomized controlled trial. Clin Endocrinol (Oxf). 2018;88(3):442–52.CrossRefPubMed
25.
Johnson S, Schiffner J, Freundl G, et al. Luteinising hormone profiles in conception and non-conception natural cycles. Eur J Contracept Reprod Health Care. 2019;24(2):140–7.CrossRefPubMed
26.
Surrey ES, Schoolcraft WB. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril. 2000;73(4):667–76.CrossRefPubMed
27.
28.
Lee HJ, Jee BC, Suh CS, et al. Oocyte maturity in relation to woman’se in vitro fertilization cycles stimulated by single regimen. Yonsei Med J. 2012;53(1):181–5.CrossRefPubMed
29.
Kahyaoglu S, Yumusak OH, Ozgu-Erdinc AS, et al. Can serum estradiol levels on the fourth day of IVF/ICSI cycle predict outcome in poor responder women? Reprod Med. 2015;61(4):233–7.
30.
Khalili MA, Shahedi A, Ashourzadeh S, et al. Vitrification of human immature oocytes before and after in vitro maturation: a review. Reprod Genet. 2017;34(11):1413–26.CrossRef
31.
Grøndahl ML, Christiansen SL, Kesmodel US, et al. Effect of women’s age on embryo morphology, cleavage te and competence a multicenter cohort study. PLoS ONE. 2017;12(4):e0172456.CrossRefPubMedPubMedCentral
32.
Golakov M, Depenbusch M, Schultze-Mosgau A, et al. What is the net effect of introducing vitrification for cryopreservation of surplus 2PN oocytes in an IVF program? Arch Gynecol Obstet. 2018;297(2):529–37.CrossRefPubMed
33.
Li XL, Huang R, Fang C, Liang XY. Basal serum Anti-Müllerian hormone level as a predictor of clinical outcomes in freezing-all embryo transfer program. Curr Med Sci. 2018;38(5):861–7.CrossRefPubMed
34.
Okunola OT, Ajenifuja OK, Loto MO, et al. Age-specific nomograms for follicle stimulating hormone and anti-mullerian hormone: a pilot study in Ile-Ife, Nigeria. Int J Reprod Biomed (Yazd). 2016;14(12):777–82.CrossRef
35.
López Martín MJ, García D, Vassena R, Rodríguez A. Oocyte developmental competence is independent of ovarian reserve in women younger than 35 years. Reprod Biomed Online. 2018;37(6):677–84.CrossRefPubMed
36.
Petanovski Z, Dimitrov G, Ajdin B, et al. Impact of body mass index (BMI) and age on the outcome of the IVF process. Prilozi. 2011;32(1):155–71.PubMed
37.
Gorkem U, Kucukler FK, Togrul C, Gulen Ş. Obesity does not compromise ovarian Reserve markers in Infertile Women. Geburtshilfe Frauenheilkd. 2019;79(1):79–85.CrossRefPubMedPubMedCentral
38.
Metadata
Title
Nomogram to predict FSH starting dose in poor ovarian response women in progestin primed ovarian stimulation protocol
Authors
Shuxie Wu
Yanping Li
Gao Wu
Hanbin Wu
Publication date
01-12-2023
Publisher
BioMed Central
Keywords
ICSI
Progestin
Published in
BMC Women's Health / Issue 1/2023
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-023-02327-x

Other articles of this Issue 1/2023

BMC Women's Health 1/2023 Go to the issue

Research

Status of common sexually transmitted infection in population referred for colposcopy and correlation with human papillomavirus infection

Research

Nutritional status and quality of life among breast Cancer patients undergoing treatment in Addis Ababa, Ethiopia

Research

Barriers to using postpartum family planning among women in Zanzibar, Tanzania

Research

What do I do to avoid sexually transmitted diseases? A scale development study: behavioral scale for protection from sexually transmitted diseases

Research

Investigating influencing factors on premenstrual syndrome (PMS) among female college students

Correction

Correction to: prevalence of pelvic floor dysfunction: a Saudi national survey